CLINICAL RESEARCH: MYOCARDIAL ISCHEMIA/INFARCTION
The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia
Steffen Sonntag*,*,
Stig Sundberg, PhD ,
Lasse Antero Lehtonen, MD and
Franz Xaver Kleber, MD*
* UKB Berlin and Free University Berlin, Berlin, Germany
Orion Corporation, Espoo, Finland
Helsinki University Central Hospital, Helsinki, Finland
Manuscript received December 2, 2002;
revised manuscript received January 18, 2004,
accepted February 18, 2004.
* Reprint requests and correspondence: Steffen Sonntag, Department Internal Medicine, UKB Berlin, Academic Teaching Hospital, Free University Berlin, Warener Strasse 07, D-12683 Berlin, Germany.
steffen.sonntag{at}snafu.de
OBJECTIVES: We assessed the effects of levosimendan on left ventricular (LV) function in patients with acute myocardial ischemia and after coronary angioplasty.
BACKGROUND: The calcium sensitizer levosimendan improves the function of myocardium in experimental stunning.
METHODS: Twenty-four patients with an acute coronary syndrome underwent angioplasty followed by double-blinded, randomized treatment with 24 µg/kg of levosimendan (n = 16) or placebo (n = 8). Left ventricular pressures and volumes were recorded by cineventriculography and micromanometer-tipped catheters 10 min after angioplasty before drug administration (baseline) and 20 min after drug administration. Left ventricular function was assessed by the pressure–volume loop, and regional function analysis by the Slager method.
RESULTS: The number of hypokinetic segments decreased with levosimendan, from 8.9 ± 0.9 to 6.5 ± 1.1 (mean ± SEM), as compared with an increase from 7.8 ± 1.0 to 8.5 ± 1.1 with placebo (p = 0.016). A leftward and/or upward shift of the systolic part of the pressure–volume loop, indicating improved systolic function, was observed in eight of 16 of the levosimendan-treated and one of eight of the placebo patients (p = 0.178). In addition, the single-beat elastance was increased by levosimendan (p = 0.045). The pressure–volume area (p = 0.001), end-systolic pressure (p = 0.002), and volume index (p < 0.001) were decreased by levosimendan, but there was no change in the end-systolic pressure–volume ratio. End-diastolic pressure remained unchanged, whereas the end-diastolic volume index was decreased by levosimendan (p = 0.002). The time constant of isovolumic LV pressure fall decreased with levosimendan (p = 0.001).
CONCLUSIONS: Levosimendan improved the function of stunned myocardium without obvious impairment of diastolic function.
|
Abbreviations and Acronyms
| | ACS | = acute coronary syndrome | | LV | = left ventricle/left ventricular | | TIMI | = Thrombolysis In Myocardial Infarction |
|
This article has been cited by other articles:
|
|
|
|
 
M. W. Dunser and W. R. Hasibeder
Sympathetic Overstimulation During Critical Illness: Adverse Effects of Adrenergic Stress
J Intensive Care Med,
September 1, 2009;
24(5):
293 - 316.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Tritapepe, V. De Santis, D. Vitale, F. Guarracino, F. Pellegrini, P. Pietropaoli, and M. Singer
Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery
Br. J. Anaesth.,
February 1, 2009;
102(2):
198 - 204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. X. Kleber, T. Bollmann, M. M. Borst, A. Costard-Jackle, R. Ewert, M. Kivikko, T. Petterson, P. Pohjanjousi, S. Sonntag, and G. Wikstrom
Repetitive Dosing of Intravenous Levosimendan Improves Pulmonary Hemodynamics in Patients With Pulmonary Hypertension: Results of a Pilot Study
J. Clin. Pharmacol.,
January 1, 2009;
49(1):
109 - 115.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tasouli, K. Papadopoulos, T. Antoniou, I. Kriaras, G. Stavridis, D. Degiannis, and S. Geroulanos
Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use
Eur. J. Cardiothorac. Surg.,
October 1, 2007;
32(4):
629 - 633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cianfrocca, F. Pelliccia, A. Auriti, V. Guido, V. Pasceri, X. Li, G. Richichi, G. Mercuro, and M. Santini
Levosimendan allows detection of contractile reserve in patients with chronic ischaemic left ventricular dysfunction and non-diagnostic dobutamine echocardiography
Eur J Heart Fail,
September 1, 2007;
9(9):
897 - 900.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Pirracchio, B. Cholley, S. De Hert, A. C. Solal, and A. Mebazaa
Diastolic heart failure in anaesthesia and critical care
Br. J. Anaesth.,
June 1, 2007;
98(6):
707 - 721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Pagel
Levosimendan in Cardiac Surgery: A Unique Drug for the Treatment of Perioperative Left Ventricular Dysfunction or Just Another Inodilator Searching for a Clinical Application?
Anesth. Analg.,
April 1, 2007;
104(4):
759 - 761.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. De Hert, S. Lorsomradee, S. Cromheecke, and P. J. Van der Linden
The Effects of Levosimendan in Cardiac Surgery Patients with Poor Left Ventricular Function
Anesth. Analg.,
April 1, 2007;
104(4):
766 - 773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Givertz, C. Andreou, C. H. Conrad, and W. S. Colucci
Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction: Alteration of Force-Frequency and Relaxation-Frequency Relationships
Circulation,
March 13, 2007;
115(10):
1218 - 1224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Garcia-Gonzalez, A. Dominguez-Rodriguez, J. J. Ferrer-Hita, P. Abreu-Gonzalez, and M. B. Munoz
Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics
Eur J Heart Fail,
November 1, 2006;
8(7):
723 - 728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. De Luca, W. S. Colucci, M. S. Nieminen, B. M. Massie, and M. Gheorghiade
Evidence-based use of levosimendan in different clinical settings
Eur. Heart J.,
August 2, 2006;
27(16):
1908 - 1920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Adamcova, M. Sterba, T. Simunek, A. Potacova, O. Popelova, and V. Gersl
Myocardial regulatory proteins and heart failure
Eur J Heart Fail,
June 1, 2006;
8(4):
333 - 342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Raja and B. S. Rayen
Levosimendan in Cardiac Surgery: Current Best Available Evidence
Ann. Thorac. Surg.,
April 1, 2006;
81(4):
1536 - 1546.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-H. Song, K. Sakurai, T. Nakayama, M. Shirakawa, H. Hagiwara, and H. Kamiya
Intracoronary Adenosine Triphosphate for Refractory Coronary Artery Spasm
Asian Cardiovasc Thorac Ann,
April 1, 2006;
14(2):
e21 - e23.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Garcia-Gonzalez, A. Dominguez-Rodriguez, and J. J. Ferrer-Hita
Utility of Levosimendan, a New Calcium Sensitizing Agent, in the Treatment of Cardiogenic Shock Due to Myocardial Stunning in Patients With ST-Elevation Myocardial Infarction: A Series of Cases
J. Clin. Pharmacol.,
June 1, 2005;
45(6):
704 - 708.
[Full Text]
[PDF]
|
|
|
|
